MicroRNAs in rhabdomyosarcoma: Pathogenetic implications and translational potentiality

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Rota, Rossella ^a   Ciarapica, Roberta ^a   Giordano, Antonio ^b,c   Miele, Lucio ^d   Locatelli, Franco ^a,e  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b TEMPLE UNIVERSITY   (United States)

^c UNIVERSITY OF SIENA   (Italy)

^d UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^e UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; POLYCOMB GROUP PROTEIN; REPRESSOR PROTEIN;

CELL FATE; DOWN REGULATION; GENE EXPRESSION; GENE SILENCING; MUSCLE DEVELOPMENT; PATHOGENESIS; PRIMARY TUMOR; REVIEW; RHABDOMYOSARCOMA; RNA TRANSLATION; SKELETAL MUSCLE; SOFT TISSUE SARCOMA; TISSUE DIFFERENTIATION; TUMOR CELL; TUMOR GROWTH; UPREGULATION; ANIMAL; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY;

ANIMALS; BASE SEQUENCE; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MUSCLE DEVELOPMENT; MUSCLE, SKELETAL; REPRESSOR PROTEINS; RHABDOMYOSARCOMA;

EID: 80053173557     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-120     Document Type: Review

References (140)

1. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843-854. 10.1016/0092-8674(93)90529-Y, 8252621.
2. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993, 75:855-862. 10.1016/0092-8674(93)90530-4, 8252622.
3. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun G. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000, 403:901-906. 10.1038/35002607, 10706289.
4. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498. 10.1038/35078107, 11373684.
5. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20. 10.1016/j.cell.2004.12.035, 15652477.
6. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN. MicroRNA genes are transcribed by RNA polymerase II. Embo J 2004, 23:4051-4060. 10.1038/sj.emboj.7600385, 524334, 15372072.
7. Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 2006, 13:1097-1101. 10.1038/nsmb1167, 17099701.
8. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009, 11:228-234. 10.1038/ncb0309-228, 19255566.
9. Martinez J, Patkaniowska A, Urlaub H, Luhrmann R, Tuschl T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 2002, 110:563-574. 10.1016/S0092-8674(02)00908-X, 12230974.
10. Leuschner PJ, Ameres SL, Kueng S, Martinez J. Cleavage of the siRNA passenger strand during RISC assembly in human cells. EMBO Rep 2006, 7:314-320. 10.1038/sj.embor.7400637, 1456892, 16439995.
11. Hutvagner G, Mlynarova L, Nap JP. Detailed characterization of the posttranscriptional gene-silencing-related small RNA in a GUS gene-silenced tobacco. Rna 2000, 6:1445-1454. 10.1017/S1355838200001096, 1370015, 11073220.
12. Mallanna SK, Rizzino A. Emerging roles of microRNAs in the control of embryonic stem cells and the generation of induced pluripotent stem cells. Dev Biol 2010, 344:16-25. 10.1016/j.ydbio.2010.05.014, 2935203, 20478297.
13. Wang Y, Russell I, Chen C. MicroRNA and stem cell regulation. Curr Opin Mol Ther 2009, 11:292-298.
14. Butcher J, Abdou H, Morin K, Liu Y. Micromanaging oligodendrocyte differentiation by noncoding RNA: toward a better understanding of the lineage commitment process. J Neurosci 2009, 29:5365-5366. 10.1523/JNEUROSCI.5976-08.2009, 19403803.
15. Gangaraju VK, Lin H. MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell Biol 2009, 10:116-125. 10.1038/nrm2621, 19165214.
16. Laurent LC. MicroRNAs in embryonic stem cells and early embryonic development. J Cell Mol Med 2008, 12:2181-2188. 10.1111/j.1582-4934.2008.00513.x, 19120702.
17. Chhabra R, Dubey R, Saini N. Cooperative and individualistic functions of the microRNAs in the miR-23a~27a~24-2 cluster and its implication in human diseases. Mol Cancer 2010, 9:232. 10.1186/1476-4598-9-232, 2940846, 20815877.
18. Di Leva G, Croce CM. Roles of small RNAs in tumor formation. Trends Mol Med 2010, 16:257-267. 10.1016/j.molmed.2010.04.001, 2885513, 20493775.
19. Tili E, Croce CM, Michaille JJ. miR-155: on the crosstalk between inflammation and cancer. Int Rev Immunol 2009, 28:264-284. 10.1080/08830180903093796, 19811312.
20. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002, 99:15524-15529. 10.1073/pnas.242606799, 137750, 12434020.
21. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:857-866. 10.1038/nrc1997, 17060945.
22. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM. MicroRNA expression and function in cancer. Trends Mol Med 2006, 12:580-587. 10.1016/j.molmed.2006.10.006, 17071139.
23. Iorio MV, Piovan C, Croce CM. Interplay between microRNAs and the epigenetic machinery: an intricate network. Biochim Biophys Acta 2010, 1799:694-701.
24. Ferretti E, De Smaele E, Miele E, Laneve P, Po A, Pelloni M, Paganelli A, Di Marcotullio L, Caffarelli E, Screpanti I, et al. Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells. Embo J 2008, 27:2616-2627. 10.1038/emboj.2008.172, 2567402, 18756266.
25. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137:1005-1017. 10.1016/j.cell.2009.04.021, 2722880, 19524505.
26. Huang TH, Esteller M. Chromatin remodeling in mammary gland differentiation and breast tumorigenesis. Cold Spring Harb Perspect Biol 2010, 2:a004515. 10.1101/cshperspect.a004515, 20610549.
27. Guessous F, Zhang Y, Kofman A, Catania A, Li Y, Schiff D, Purow B, Abounader R. microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle 2010, 9.
28. Taulli R, Bersani F, Ponzetto C. Micro-orchestrating differentiation in cancer. Cell Cycle 2010, 9:918-922. 10.4161/cc.9.5.10864, 20160508.
29. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, Bader AG. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010, 70:5923-5930. 10.1158/0008-5472.CAN-10-0655, 2913706, 20570894.
30. Mishra PJ, Merlino G. MicroRNA reexpression as differentiation therapy in cancer. J Clin Invest 2009, 119:2119-2123. 2719926, 19620782.
31. Tapscott SJ, Thayer MJ, Weintraub H. Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science 1993, 259:1450-1453. 10.1126/science.8383879, 8383879.
32. De Giovanni C, Landuzzi L, Nicoletti G, Lollini PL, Nanni P. Molecular and cellular biology of rhabdomyosarcoma. Future Oncol 2009, 5:1449-1475. 10.2217/fon.09.97, 19903072.
33. Loeb DM, Thornton K, Shokek O. Pediatric soft tissue sarcomas. Surg Clin North Am 2008, 88:615-627. vii, 10.1016/j.suc.2008.03.008, 18514702.
34. Kohashi K, Oda Y, Yamamoto H, Tamiya S, Takahira T, Takahashi Y, Tajiri T, Taguchi T, Suita S, Tsuneyoshi M. Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype. J Cancer Res Clin Oncol 2008, 134:1097-1103. 10.1007/s00432-008-0385-3, 18386058.
35. Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, Breneman J, Qualman SJ, Wiener E, Wharam M, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001, 19:3091-3102.
36. Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ, Barr FG. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 2002, 20:2672-2679. 10.1200/JCO.2002.03.137, 12039929.
37. Wachtel M, Dettling M, Koscielniak E, Stegmaier S, Treuner J, Simon-Klingenstein K, Buhlmann P, Niggli FK, Schafer BW. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 2004, 64:5539-5545. 10.1158/0008-5472.CAN-04-0844, 15313887.
38. Lae M, Ahn EH, Mercado GE, Chuai S, Edgar M, Pawel BR, Olshen A, Barr FG, Ladanyi M. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas. J Pathol 2007, 212:143-151. 10.1002/path.2170, 17471488.
39. Kelly KM, Womer RB, Sorensen PH, Xiong QB, Barr FG. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. J Clin Oncol 1997, 15:1831-1836.
40. Davicioni E, Anderson MJ, Finckenstein FG, Lynch JC, Qualman SJ, Shimada H, Schofield DE, Buckley JD, Meyer WH, Sorensen PH, Triche TJ. Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am J Pathol 2009, 174:550-564. 10.2353/ajpath.2009.080631, 2630563, 19147825.
41. Williamson D, Missiaglia E, de Reynies A, Pierron G, Thuille B, Palenzuela G, Thway K, Orbach D, Lae M, Freneaux P, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 2010, 28:2151-2158. 10.1200/JCO.2009.26.3814, 20351326.
42. Wachtel M, Runge T, Leuschner I, Stegmaier S, Koscielniak E, Treuner J, Odermatt B, Behnke S, Niggli FK, Schafer BW. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol 2006, 24:816-822. 10.1200/JCO.2005.03.4934, 16391296.
43. Davicioni E, Anderson JR, Buckley JD, Meyer WH, Triche TJ. Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group. J Clin Oncol 2010, 28:1240-1246. 10.1200/JCO.2008.21.1268, 3040045, 20124188.
44. Barr FG, Qualman SJ, Macris MH, Melnyk N, Lawlor ER, Strzelecki DM, Triche TJ, Bridge JA, Sorensen PH. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. Cancer Res 2002, 62:4704-4710.
45. Gougelet A, Perez J, Pissaloux D, Besse A, Duc A, Decouvelaere AV, Ranchere-Vince D, Blay JY, Alberti L. miRNA Profiling: How to Bypass the Current Difficulties in the Diagnosis and Treatment of Sarcomas. Sarcoma 2011, 2011:460650. 3061295, 21437224.
46. O'Rourke JR, Georges SA, Seay HR, Tapscott SJ, McManus MT, Goldhamer DJ, Swanson MS, Harfe BD. Essential role for Dicer during skeletal muscle development. Dev Biol 2007, 311:359-368. 10.1016/j.ydbio.2007.08.032, 2753295, 17936265.
47. McCarthy JJ. MicroRNA-206: the skeletal muscle-specific myomiR. Biochim Biophys Acta 2008, 1779:682-691. 2656394, 18381085.
48. Anderson C, Catoe H, Werner R. MIR-206 regulates connexin43 expression during skeletal muscle development. Nucleic Acids Res 2006, 34:5863-5871. 10.1093/nar/gkl743, 1635318, 17062625.
49. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL, Wang DZ. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006, 38:228-233. 10.1038/ng1725, 2538576, 16380711.
50. Kim HK, Lee YS, Sivaprasad U, Malhotra A, Dutta A. Muscle-specific microRNA miR-206 promotes muscle differentiation. J Cell Biol 2006, 174:677-687. 10.1083/jcb.200603008, 2064311, 16923828.
51. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002, 12:735-739. 10.1016/S0960-9822(02)00809-6, 12007417.
52. Rosenberg MI, Georges SA, Asawachaicharn A, Analau E, Tapscott SJ. MyoD inhibits Fstl1 and Utrn expression by inducing transcription of miR-206. J Cell Biol 2006, 175:77-85. 10.1083/jcb.200603039, 2064500, 17030984.
53. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007, 316:575-579. 10.1126/science.1139089, 17379774.
54. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433:769-773. 10.1038/nature03315, 15685193.
55. Ivey KN, Muth A, Arnold J, King FW, Yeh RF, Fish JE, Hsiao EC, Schwartz RJ, Conklin BR, Bernstein HS, Srivastava D. MicroRNA regulation of cell lineages in mouse and human embryonic stem cells. Cell Stem Cell 2008, 2:219-229. 10.1016/j.stem.2008.01.016, 2293325, 18371447.
56. Potthoff MJ, Olson EN, Bassel-Duby R. Skeletal muscle remodeling. Curr Opin Rheumatol 2007, 19:542-549. 10.1097/BOR.0b013e3282efb761, 17917533.
57. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 2005, 436:214-220. 10.1038/nature03817, 15951802.
58. Liu N, Williams AH, Kim Y, McAnally J, Bezprozvannaya S, Sutherland LB, Richardson JA, Bassel-Duby R, Olson EN. An intragenic MEF2-dependent enhancer directs muscle-specific expression of microRNAs 1 and 133. Proc Natl Acad Sci USA 2007, 104:20844-20849. 10.1073/pnas.0710558105, 2409229, 18093911.
59. Rao PK, Kumar RM, Farkhondeh M, Baskerville S, Lodish HF. Myogenic factors that regulate expression of muscle-specific microRNAs. Proc Natl Acad Sci USA 2006, 103:8721-8726. 10.1073/pnas.0602831103, 1482645, 16731620.
60. Sweetman D, Goljanek K, Rathjen T, Oustanina S, Braun T, Dalmay T, Munsterberg A. Specific requirements of MRFs for the expression of muscle specific microRNAs, miR-1, miR-206 and miR-133. Dev Biol 2008, 321:491-499. 10.1016/j.ydbio.2008.06.019, 18619954.
61. Sokol NS, Ambros V. Mesodermally expressed Drosophila microRNA-1 is regulated by Twist and is required in muscles during larval growth. Genes Dev 2005, 19:2343-2354. 10.1101/gad.1356105, 1240043, 16166373.
62. Simon DJ, Madison JM, Conery AL, Thompson-Peer KL, Soskis M, Ruvkun GB, Kaplan JM, Kim JK. The microRNA miR-1 regulates a MEF-2-dependent retrograde signal at neuromuscular junctions. Cell 2008, 133:903-915. 10.1016/j.cell.2008.04.035, 2553566, 18510933.
63. Zhao X, Sternsdorf T, Bolger TA, Evans RM, Yao TP. Regulation of MEF2 by histone deacetylase 4- and SIRT1 deacetylase-mediated lysine modifications. Mol Cell Biol 2005, 25:8456-8464. 10.1128/MCB.25.19.8456-8464.2005, 1265742, 16166628.
64. Williams AH, Valdez G, Moresi V, Qi X, McAnally J, Elliott JL, Bassel-Duby R, Sanes JR, Olson EN. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 2009, 326:1549-1554. 10.1126/science.1181046, 2796560, 20007902.
65. Sun Y, Ge Y, Drnevich J, Zhao Y, Band M, Chen J. Mammalian target of rapamycin regulates miRNA-1 and follistatin in skeletal myogenesis. J Cell Biol 2010, 189:1157-1169. 10.1083/jcb.200912093, 2894448, 20566686.
66. Chen JF, Tao Y, Li J, Deng Z, Yan Z, Xiao X, Wang DZ. microRNA-1 and microRNA-206 regulate skeletal muscle satellite cell proliferation and differentiation by repressing Pax7. J Cell Biol 2010, 190:867-879. 10.1083/jcb.200911036, 2935565, 20819939.
67. Dey BK, Gagan J, Dutta A. miR-206 and -486 induce myoblast differentiation by downregulating Pax7. Mol Cell Biol 2010, 31:203-214. 3019853, 21041476.
68. Hirai H, Verma M, Watanabe S, Tastad C, Asakura Y, Asakura A. MyoD regulates apoptosis of myoblasts through microRNA-mediated down-regulation of Pax3. J Cell Biol 2010, 191:347-365. 10.1083/jcb.201006025, 2958479, 20956382.
69. Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, Muth AN, Tsuchihashi T, McManus MT, Schwartz RJ, Srivastava D. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007, 129:303-317. 10.1016/j.cell.2007.03.030, 17397913.
70. Liu N, Bezprozvannaya S, Williams AH, Qi X, Richardson JA, Bassel-Duby R, Olson EN. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 2008, 22:3242-3254. 10.1101/gad.1738708, 2600761, 19015276.
71. Williams AH, Liu N, van Rooij E, Olson EN. MicroRNA control of muscle development and disease. Curr Opin Cell Biol 2009, 21:461-469. 10.1016/j.ceb.2009.01.029, 2692369, 19278845.
72. Sarkar S, Dey BK, Dutta A. MiR-322/424 and -503 are induced during muscle differentiation and promote cell cycle quiescence and differentiation by down-regulation of Cdc25A. Mol Biol Cell 2010, 21:2138-2149. 10.1091/mbc.E10-01-0062, 2893979, 20462953.
73. Crist CG, Montarras D, Pallafacchina G, Rocancourt D, Cumano A, Conway SJ, Buckingham M. Muscle stem cell behavior is modified by microRNA-27 regulation of Pax3 expression. Proc Natl Acad Sci USA 2009, 106:13383-13387. 10.1073/pnas.0900210106, 2726381, 19666532.
74. Gagan J, Dey BK, Layer R, Yan Z, Dutta A. MICRORNA-378 targets the myogenic repressor myor during myoblast differentiation. J Biol Chem 2011,
75. Naguibneva I, Ameyar-Zazoua M, Polesskaya A, Ait-Si-Ali S, Groisman R, Souidi M, Cuvellier S, Harel-Bellan A. The microRNA miR-181 targets the homeobox protein Hox-A11 during mammalian myoblast differentiation. Nat Cell Biol 2006, 8:278-284. 10.1038/ncb1373, 16489342.
76. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J, Cheng A, Hall BM, Qualman SJ, Chandler DS, et al. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 2008, 14:369-381. 10.1016/j.ccr.2008.10.006, 18977326.
77. Wong CF, Tellam RL. MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis. J Biol Chem 2008, 283:9836-9843. 10.1074/jbc.M709614200, 18281287.
78. Juan AH, Kumar RM, Marx JG, Young RA, Sartorelli V. Mir-214-dependent regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic stem cells. Mol Cell 2009, 36:61-74. 10.1016/j.molcel.2009.08.008, 2761245, 19818710.
79. Levine SS, King IF, Kingston RE. Division of labor in polycomb group repression. Trends Biochem Sci 2004, 29:478-485. 10.1016/j.tibs.2004.07.007, 15337121.
80. Marx J. Developmental biology. Combing over the Polycomb group proteins. Science 2005, 308:624-626. 10.1126/science.308.5722.624, 15860605.
81. Caretti G, Di Padova M, Micales B, Lyons GE, Sartorelli V. The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev 2004, 18:2627-2638. 10.1101/gad.1241904, 525543, 15520282.
82. Palacios D, Mozzetta C, Consalvi S, Caretti G, Saccone V, Proserpio V, Marquez VE, Valente S, Mai A, Forcales SV, et al. TNF/p38alpha/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell 2010, 7:455-469. 10.1016/j.stem.2010.08.013, 2951277, 20887952.
83. Liu J, Luo XJ, Xiong AW, Zhang ZD, Yue S, Zhu MS, Cheng SY. MicroRNA-214 promotes myogenic differentiation by facilitating exit from mitosis via down-regulation of proto-oncogene N-ras. J Biol Chem 2010, 285:26599-26607. 10.1074/jbc.M110.115824, 2924098, 20534588.
84. Wang H, Hertlein E, Bakkar N, Sun H, Acharyya S, Wang J, Carathers M, Davuluri R, Guttridge DC. NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Mol Cell Biol 2007, 27:4374-4387. 10.1128/MCB.02020-06, 1900043, 17438126.
85. Ciarapica R, Russo G, Verginelli F, Raimondi L, Donfrancesco A, Rota R, Giordano A. Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma. Cell Cycle 2009, 8:172-175. 10.4161/cc.8.1.7292, 19106613.
86. Taulli R, Bersani F, Foglizzo V, Linari A, Vigna E, Ladanyi M, Tuschl T, Ponzetto C. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest 2009, 119:2366-2378. 2719932, 19620785.
87. Yan D, Dong Xda E, Chen X, Wang L, Lu C, Wang J, Qu J, Tu L. MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem 2009, 284:29596-29604. 10.1074/jbc.M109.020511, 2785592, 19710019.
88. Rao PK, Missiaglia E, Shields L, Hyde G, Yuan B, Shepherd CJ, Shipley J, Lodish HF. Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells. Faseb J 2010, 24:3427-3437. 10.1096/fj.09-150698, 20466878.
89. Mottet D, Pirotte S, Lamour V, Hagedorn M, Javerzat S, Bikfalvi A, Bellahcene A, Verdin E, Castronovo V. HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene 2009, 28:243-256. 10.1038/onc.2008.371, 18850004.
90. Winbanks CE, Wang B, Beyer C, Koh P, White L, Kantharidis P, Gregorevic P. TGF-{beta} regulates miR-206 and miR-29 to control myogenic differentiation through regulation of histone deacetylase 4 (HDAC4). J Biol Chem 2011,
91. Wachtel M, Schafer BW. Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev 2010, 36:318-327. 10.1016/j.ctrv.2010.02.007, 20223596.
92. Subramanian S, Lui WO, Lee CH, Espinosa I, Nielsen TO, Heinrich MC, Corless CL, Fire AZ, van de Rijn M. MicroRNA expression signature of human sarcomas. Oncogene 2008, 27:2015-2026. 10.1038/sj.onc.1210836, 17922033.
93. Li Z, Hassan MQ, Jafferji M, Aqeilan RI, Garzon R, Croce CM, van Wijnen AJ, Stein JL, Stein GS, Lian JB. Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. J Biol Chem 2009, 284:15676-15684. 10.1074/jbc.M809787200, 2708864, 19342382.
94. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007, 104:15805-15810. 10.1073/pnas.0707628104, 2000384, 17890317.
95. Song G, Wang L. Nuclear receptor SHP activates miR-206 expression via a cascade dual inhibitory mechanism. PLoS One 2009, 4:e6880. 10.1371/journal.pone.0006880, 2730526, 19721712.
96. Sarver AL, Li L, Subramanian S. MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. Cancer Res 2010, 70:9570-9580. 10.1158/0008-5472.CAN-10-2074, 21118966.
97. Gordon AT, Brinkschmidt C, Anderson J, Coleman N, Dockhorn-Dworniczak B, Pritchard-Jones K, Shipley J. A novel and consistent amplicon at 13q31 associated with alveolar rhabdomyosarcoma. Genes Chromosomes Cancer 2000, 28:220-226. 10.1002/(SICI)1098-2264(200006)28:2<220::AID-GCC11>3.0.CO;2-T, 10825007.
98. Williamson D, Selfe J, Gordon T, Lu YJ, Pritchard-Jones K, Murai K, Jones P, Workman P, Shipley J. Role for amplification and expression of glypican-5 in rhabdomyosarcoma. Cancer Res 2007, 67:57-65. 10.1158/0008-5472.CAN-06-1650, 17210683.
99. Reichek JL, Duan F, Smith LM, Gustafson DM, O'Connor RS, Zhang C, Dunlevy MJ, Gastier-Foster JM, Barr FG. Genomic and Clinical Analysis of Amplification of the 13q31 Chromosomal Region in Alveolar Rhabdomyosarcoma: A Report from the Children's Oncology Group. Clin Cancer Res 2011, 17:1463-1473. 10.1158/1078-0432.CCR-10-0091, 21220470.
100. Wei JS, Johansson P, Chen QR, Song YK, Durinck S, Wen X, Cheuk AT, Smith MA, Houghton P, Morton C, Khan J. microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies. Clin Cancer Res 2009, 15:5560-5568. 10.1158/1078-0432.CCR-08-3287, 2737097, 19706822.
101. Missiaglia E, Shepherd CJ, Patel S, Thway K, Pierron G, Pritchard-Jones K, Renard M, Sciot R, Rao P, Oberlin O, et al. MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas. Br J Cancer 2010, 102:1769-1777. 10.1038/sj.bjc.6605684, 2883695, 20502458.
102. Morotti RA, Nicol KK, Parham DM, Teot LA, Moore J, Hayes J, Meyer W, Qualman SJ. An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's Oncology Group experience. Am J Surg Pathol 2006, 30:962-968. 10.1097/00000478-200608000-00005, 16861966.
103. Heerema-McKenney A, Wijnaendts LC, Pulliam JF, Lopez-Terrada D, McKenney JK, Zhu S, Montgomery K, Mitchell J, Marinelli RJ, Hart AA, et al. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype. Am J Surg Pathol 2008, 32:1513-1522. 10.1097/PAS.0b013e31817a909a, 18708938.
104. Brase JC, Wuttig D, Kuner R, Sultmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 2010, 9:306. 10.1186/1476-4598-9-306, 3002336, 21110877.
105. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006. 10.1038/cr.2008.282, 18766170.
106. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, Benjamin H, Kushnir M, Cholakh H, Melamed N, et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008, 3:e3148. 10.1371/journal.pone.0003148, 2519789, 18773077.
107. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008, 105:10513-10518. 10.1073/pnas.0804549105, 2492472, 18663219.
108. Miyachi M, Tsuchiya K, Yoshida H, Yagyu S, Kikuchi K, Misawa A, Iehara T, Hosoi H. Circulating muscle-specific microRNA, miR-206, as a potential diagnostic marker for rhabdomyosarcoma. Biochem Biophys Res Commun 2010, 400:89-93. 10.1016/j.bbrc.2010.08.015, 20696132.
109. Hays DM, Lawrence W, Wharam M, Newton W, Ruymann FB, Beltangady M, Maurer HM. Primary reexcision for patients with 'microscopic residual' tumor following initial excision of sarcomas of trunk and extremity sites. J Pediatr Surg 1989, 24:5-10. 10.1016/S0022-3468(89)80290-8, 2723995.
110. Lawrence W, Hays DM, Heyn R, Beltangady M, Maurer HM. Surgical lessons from the Intergroup Rhabdomyosarcoma Study (IRS) pertaining to extremity tumors. World J Surg 1988, 12:676-684. 10.1007/BF01655884, 3072777.
111. Gaarz A, Debey-Pascher S, Classen S, Eggle D, Gathof B, Chen J, Fan JB, Voss T, Schultze JL, Staratschek-Jox A. Bead array-based microrna expression profiling of peripheral blood and the impact of different RNA isolation approaches. J Mol Diagn 2010, 12:335-344. 10.2353/jmoldx.2010.090116, 2860470, 20228267.
112. Heneghan HM, Miller N, Kerin MJ. Circulating miRNA signatures: promising prognostic tools for cancer. J Clin Oncol 2010, 28:e573-574. author reply e575-576, 10.1200/JCO.2010.29.8901, 20697097.
113. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011,
114. Gee HE, Buffa FM, Camps C, Ramachandran A, Leek R, Taylor M, Patil M, Sheldon H, Betts G, Homer J, et al. The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br J Cancer 2011, 104:1168-1177. 10.1038/sj.bjc.6606076, 21407217.
115. Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello GS, Banerjee D, Bertino JR. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci USA 2007, 104:13513-13518. 10.1073/pnas.0706217104, 1948927, 17686970.
116. To KK, Zhan Z, Litman T, Bates SE. Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol Cell Biol 2008, 28:5147-5161. 10.1128/MCB.00331-08, 2519722, 18573883.
117. Chen CF, He X, Arslan AD, Mo YY, Reinhold WC, Pommier Y, Beck WT. Novel Regulation of Nuclear Factor-YB by miR-485-3p Affects the Expression of DNA Topoisomerase II{alpha} and Drug Responsiveness. Mol Pharmacol 2011, 79:735-741. 10.1124/mol.110.069633, 21252292.
118. Cortez MA, Calin GA. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther 2009, 9:703-711. 10.1517/14712590902932889, 19426115.
119. Pirollo KF, Rait A, Zhou Q, Hwang SH, Dagata JA, Zon G, Hogrefe RI, Palchik G, Chang EH. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res 2007, 67:2938-2943. 10.1158/0008-5472.CAN-06-4535, 17409398.
120. Hogrefe RI, Lebedev AV, Zon G, Pirollo KF, Rait A, Zhou Q, Yu W, Chang EH. Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2. Nucleosides Nucleotides Nucleic Acids 2006, 25:889-907. 10.1080/15257770600793885, 16901821.
121. Su J, Baigude H, McCarroll J, Rana TM. Silencing microRNA by interfering nanoparticles in mice. Nucleic Acids Res 2011, 39:e38. 10.1093/nar/gkq1307, 3064800, 21212128.
122. Anand S, Majeti BK, Acevedo LM, Murphy EA, Mukthavaram R, Scheppke L, Huang M, Shields DJ, Lindquist JN, Lapinski PE, et al. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med 2010, 16:909-914. 10.1038/nm.2186, 3094020, 20676106.
123. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, Lindholm M, Hedtjarn M, Hansen HF, Berger U, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008, 452:896-899. 10.1038/nature06783, 18368051.
124. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, Orum H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327:198-201. 10.1126/science.1178178, 19965718.
125. Vigil CE, Martin-Santos T, Garcia-Manero G. Safety and efficacy of azacitidine in myelodysplastic syndromes. Drug Des Devel Ther 2010, 4:221-229. 2948932, 20957213.
126. Candelaria M, Herrera A, Labardini J, Gonzalez-Fierro A, Trejo-Becerril C, Taja-Chayeb L, Perez-Cardenas E, de la Cruz-Hernandez E, Arias-Bofill D, Vidal S, et al. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. Ann Hematol 2010, 90:379-387.
127. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, et al. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 2010,
128. Suva ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino D, Cironi L, et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 2009, 69:9211-9218. 10.1158/0008-5472.CAN-09-1622, 19934320.
129. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET, Yu Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007, 21:1050-1063. 10.1101/gad.1524107, 1855231, 17437993.
130. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, Ustun C, Rao R, Fernandez P, Chen J, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009, 114:2733-2743. 2756128, 19638619.
131. Hayden A, Johnson PW, Packham G, Crabb SJ. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. Breast Cancer Res Treat
132. Kalushkova A, Fryknas M, Lemaire M, Fristedt C, Agarwal P, Eriksson M, Deleu S, Atadja P, Osterborg A, Nilsson K, et al. Polycomb target genes are silenced in multiple myeloma. PLoS One 2010, 5:e11483. 10.1371/journal.pone.0011483, 2901331, 20634887.
133. Han L, Witmer PD, Casey E, Valle D, Sukumar S. DNA methylation regulates MicroRNA expression. Cancer Biol Ther 2007, 6:1284-1288.
134. Brueckner B, Stresemann C, Kuner R, Mund C, Musch T, Meister M, Sultmann H, Lyko F. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 2007, 67:1419-1423. 10.1158/0008-5472.CAN-06-4074, 17308078.
135. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007, 67:8699-8707. 10.1158/0008-5472.CAN-07-1936, 17875710.
136. Lu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res 2007, 67:10117-10122. 10.1158/0008-5472.CAN-07-2544, 17974952.
137. Yu Y, Zeng P, Xiong J, Liu Z, Berger SL, Merlino G. Epigenetic drugs can stimulate metastasis through enhanced expression of the pro-metastatic Ezrin gene. PLoS One 2010, 5:e12710. 10.1371/journal.pone.0012710, 2938331, 20856924.
138. Li WQ, Li YM, Tao BB, Lu YC, Hu GH, Liu HM, He J, Xu Y, Yu HY. Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease their chemoresistance. Med Sci Monit 2010, 16:HY27-30.
139. Mongroo PS, Rustgi AK. The role of the miR-200 family in epithelial-mesenchymal transition. Cancer Biol Ther 2010, 10:219-222. 10.4161/cbt.10.3.12548, 3040834, 20592490.
140. Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 2010, 46:298-311. 10.1016/j.ejca.2009.10.027, 19948396.